by Olga Deshchenko
, DOTmed News Reporter | July 05, 2011
Eckert & Ziegler, a German isotope technology company, announced Tuesday it entered into an agreement with Bioscan, Inc., to acquire its radiopharmaceutical equipment business.
Under the terms of the agreement, Eckert & Ziegler will acquire Bioscan's Radiochemistry and Analytic Instrumentation product lines, which include analytical instruments for quality assurance of radioactive pharmaceuticals and automated radiopharmaceutical synthesis units, according to the release announcing the acquisition.
According to Berlin-based Eckert & Ziegler, the acquisition will enable the company to broaden its reach into the North American market and expand its developing equipment business.
The Washington, DC-based Bioscan said the deal will enable the company to boost investment in its preclinical imaging product line.
Bioscan's preclinical imaging business grew to become well over 80 percent of the company's total business since it launched about four years ago, Alex Kleinman, Bioscan's vice president of marketing and business development, told DOTmed News. “It seemed appropriate to reinvest and refocus our business on imaging for that reason," he said.
According to Kleinman, Bioscan was glad to find such a prominent market player as Eckert & Ziegler to acquire its radiopharmaceutical equipment business. "There’s a lot of equipment out there with the Bioscan brand name on it and we want to make sure that customers receive the support that they’ve been accustomed to," Kleinman said.
With 550 employees worldwide, Eckert & Ziegler: Eckert & Ziegler Strahlen- und Medizintechnik AG is a holding company for several specialized subsidiaries involved in the processing and development of radioisotopes and the sales of isotope technical components and medical devices.
Bioscan is a supplier of preclinical nano-tomographic molecular imaging systems. Its SPECT, PET, optical and X-ray CT imaging tools are used by more than 100 academic institutions and research entities.
Financial terms of the acquisition were not made public. The agreement took effect July 1.